Orphan designation: zimberelimab Treatment of gastric cancer, 12/09/2025 Positive
Submitted by Anonymous (not verified) on 26 March 2026 - 12:55
Orphan designation: zimberelimab Treatment of gastric cancer, 12/09/2025 Positive
Orphan designation: adeno-associated virus vector serotype 6.2 containing human TERT gene Treatment of idiopathic pulmonary fibrosis, 12/09/2025 Positive
Submitted by Anonymous (not verified) on 26 March 2026 - 12:53
Orphan designation: adeno-associated virus vector serotype 6.2 containing human TERT gene Treatment of idiopathic pulmonary fibrosis, 12/09/2025 Positive
Orphan designation: iniparib Treatment of glioma, 12/09/2025 Positive
Submitted by Anonymous (not verified) on 26 March 2026 - 12:51
Orphan designation: iniparib Treatment of glioma, 12/09/2025 Positive
Orphan designation: potravitug Treatment in solid organ transplantation, 15/12/2025 Positive
Submitted by Anonymous (not verified) on 26 March 2026 - 12:45
Orphan designation: potravitug Treatment in solid organ transplantation, 15/12/2025 Positive
Vaccine-preventable diseases: key facts
Submitted by Anonymous (not verified) on 26 March 2026 - 12:26
Vaccine-preventable diseases: key facts
Vaccine Essentials: Supporting vaccine literacy
Submitted by Anonymous (not verified) on 26 March 2026 - 12:23
Vaccine Essentials: Supporting vaccine literacy
Vaccine Essentials: Meningococcal group B vaccines - facts and figures overview
Submitted by Anonymous (not verified) on 26 March 2026 - 12:22
Vaccine Essentials: Meningococcal group B vaccines - facts and figures overview
Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 26 March 2026 - 11:28
Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 28, Status: Authorised
Pharmaceutical quality system (PQS) effectiveness pilot project
Submitted by Anonymous (not verified) on 26 March 2026 - 9:40
Pharmaceutical quality system (PQS) effectiveness pilot project
3Rs Working Party (3RsWP) stakeholder meeting - Public session on the 2026-2028 work plan, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 31 March 2026, 09:30 (CEST) to 31 March 2026, 10:30 (CEST)
Submitted by Anonymous (not verified) on 26 March 2026 - 8:25
3Rs Working Party (3RsWP) stakeholder meeting - Public session on the 2026-2028 work plan, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 31 March 2026, 09:30 (CEST) to 31 March 2026, 10:30 (CEST)